View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAtreca 향후 성장Future 기준 점검 0/6Atreca의 수익이 할 전망입니다. 주당 순이익은 성장 연간 25.8%만큼 감소할 것으로 예상됩니다.핵심 정보8.9%이익 성장률25.75%EPS 성장률Biotechs 이익 성장23.2%매출 성장률n/a향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트23 Feb 2024최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 06Atreca, Inc. Announces Resignation of Franklin Berger from the BoardOn May 13, 2024, Mr. Franklin Berger resigned from the board of Atreca, Inc. Accordingly, Mr. Berger now serves on the boards of directors of three other public companies in addition to the Atea Board (Satellos Bioscience Inc., ESSA Pharma Inc., and Kezar Life Sciences, Inc.).공시 • May 21Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL) for $12.5 million on December 22, 2023. Pursuant to the agreement, Immunome will pay an aggregate purchase price of up to $12.5 million in cash, with $5.5 million due to the Atreca at the closing of the agreemeny and up to $7 million due upon the achievement of certain clinical-based milestone. The agreement have been unanimously approved by the board of directors of the Atreca. The agreement must also be approved by the Atreca’s stockholders, as a condition to the closing. In certain circumtances Atreca will pay a termination fee of $0.5 million to Immunome. Transaction is expected to close in the second quarter of 2024. John T. McKenna and Matthew Silverman of Cooley LLP acted as legal advisor to Atreca. Kingsley Taft and Steven Green of Goodwin Procter LLP acted as legal advisor to Immunome.Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL) on May 20, 2024.공시 • Apr 02Atreca, Inc. Files Form 15Atreca, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Class A Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Class A Common Stock was $0.0001 per share.공시 • Mar 21Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI IndexAtreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index공시 • Mar 19Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite IndexAtreca, Inc. has been dropped from NASDAQ Composite Index .공시 • Mar 12Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid RequirementAs previously reported, on September 8, 2023, Atreca, Inc. (the Company") received written notification (the Initial Notice") from The Nasdaq Stock Market LLC (Nasdaq") notifying it that on September 7, 2023, the average closing price of the Company's Class A common stock, $0.0001 par value per share (the Class A Common Stock"), over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had 180 calendar days from the date of the Initial Notice, or March 6, 2024, to regain compliance with the Minimum Bid Requirement (the Grace Period"), subject to a potential 180-day extension. To regain compliance, the closing bid price of the Class A Common Stock must have been at least $1.00 per share for a minimum of ten consecutive business days within the Grace Period. On March 8, 2024, the Company received written notification from Nasdaq indicating that it had failed to achieve compliance with the Minimum Bid Requirement prior to the expiration of the Grace Period, and therefore the Class A Common Stock will be delisted from trading on Nasdaq. The Company does not intend to request an extension of the Grace Period or any administrative hearing to delay such delisting. As a result, the Class A Common Stock will be suspended from trading at the opening of business on March 19, 2024. Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission (the SEC") to remove the Class A Common Stock from listing and registration, though Nasdaq has not specified the date on which the Form 25-NSE will be filed. If Nasdaq has not filed the Form 25-NSE by March 20, 2024, the Company intends to file a Form 25 with the SEC on such date to remove the Class A Common Stock from listing and registration on Nasdaq. The Company plans to file a Form 15with the SEC to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended, shortly thereafter. The Company expects that its Class A Common Stock will be eligible to be quoted over-the-counter," however, no assurance can be given that quotation of the Class A Common Stock will be commenced or maintained on an over-the-counter market or any other quotation medium.New Risk • Feb 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$65m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$65m free cash flow). Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (€8.54m market cap, or US$9.19m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$51m net loss in 3 years).Board Change • Jan 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Independent Director Stacey Ma was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Independent Director Stacey Ma was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.이익 및 매출 성장 예측MUN:0C1 - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2026N/A-52N/AN/A112/31/2025N/A-48N/AN/A212/31/2024N/A-43N/AN/A212/31/2023N/A-80N/AN/A29/30/2023N/A-98-65-65N/A6/30/2023N/A-85-65-64N/A3/31/2023N/A-93-71-70N/A12/31/2022N/A-97-82-81N/A9/30/2022N/A-105-86-81N/A6/30/2022N/A-110-88-81N/A3/31/2022N/A-108-93-69N/A12/31/2021N/A-109-96-61N/A9/30/2021N/A-103-96-63N/A6/30/2021N/A-98-93-62N/A3/31/2021N/A-92-82-66N/A12/31/2020N/A-86-72-67N/A9/30/2020N/A-83-70-65N/A6/30/2020N/A-76-71-65N/A3/31/2020N/A-74-67-63N/A12/31/2019N/A-67-62-59N/A9/30/2019N/A-59-56-53N/A6/30/2019N/A-53-47-45N/A3/31/2019N/A-44-41-40N/A12/31/2018N/A-38-36-35N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 0C1 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: 0C1 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: 0C1 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: 0C1 의 수익이 German 시장보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 매출: 0C1 은(는) 내년에 수익이 없을 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 0C1의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/04/17 09:36종가2024/01/19 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Atreca, Inc.는 11명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael UlzBairdKumaraguru RajaBrookline Capital MarketsJohn NewmanCanaccord Genuity8명의 분석가 더 보기
공시 • Jun 06Atreca, Inc. Announces Resignation of Franklin Berger from the BoardOn May 13, 2024, Mr. Franklin Berger resigned from the board of Atreca, Inc. Accordingly, Mr. Berger now serves on the boards of directors of three other public companies in addition to the Atea Board (Satellos Bioscience Inc., ESSA Pharma Inc., and Kezar Life Sciences, Inc.).
공시 • May 21Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL) for $12.5 million on December 22, 2023. Pursuant to the agreement, Immunome will pay an aggregate purchase price of up to $12.5 million in cash, with $5.5 million due to the Atreca at the closing of the agreemeny and up to $7 million due upon the achievement of certain clinical-based milestone. The agreement have been unanimously approved by the board of directors of the Atreca. The agreement must also be approved by the Atreca’s stockholders, as a condition to the closing. In certain circumtances Atreca will pay a termination fee of $0.5 million to Immunome. Transaction is expected to close in the second quarter of 2024. John T. McKenna and Matthew Silverman of Cooley LLP acted as legal advisor to Atreca. Kingsley Taft and Steven Green of Goodwin Procter LLP acted as legal advisor to Immunome.Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL) on May 20, 2024.
공시 • Apr 02Atreca, Inc. Files Form 15Atreca, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Class A Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Class A Common Stock was $0.0001 per share.
공시 • Mar 21Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI IndexAtreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index
공시 • Mar 19Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite IndexAtreca, Inc. has been dropped from NASDAQ Composite Index .
공시 • Mar 12Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid RequirementAs previously reported, on September 8, 2023, Atreca, Inc. (the Company") received written notification (the Initial Notice") from The Nasdaq Stock Market LLC (Nasdaq") notifying it that on September 7, 2023, the average closing price of the Company's Class A common stock, $0.0001 par value per share (the Class A Common Stock"), over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had 180 calendar days from the date of the Initial Notice, or March 6, 2024, to regain compliance with the Minimum Bid Requirement (the Grace Period"), subject to a potential 180-day extension. To regain compliance, the closing bid price of the Class A Common Stock must have been at least $1.00 per share for a minimum of ten consecutive business days within the Grace Period. On March 8, 2024, the Company received written notification from Nasdaq indicating that it had failed to achieve compliance with the Minimum Bid Requirement prior to the expiration of the Grace Period, and therefore the Class A Common Stock will be delisted from trading on Nasdaq. The Company does not intend to request an extension of the Grace Period or any administrative hearing to delay such delisting. As a result, the Class A Common Stock will be suspended from trading at the opening of business on March 19, 2024. Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission (the SEC") to remove the Class A Common Stock from listing and registration, though Nasdaq has not specified the date on which the Form 25-NSE will be filed. If Nasdaq has not filed the Form 25-NSE by March 20, 2024, the Company intends to file a Form 25 with the SEC on such date to remove the Class A Common Stock from listing and registration on Nasdaq. The Company plans to file a Form 15with the SEC to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended, shortly thereafter. The Company expects that its Class A Common Stock will be eligible to be quoted over-the-counter," however, no assurance can be given that quotation of the Class A Common Stock will be commenced or maintained on an over-the-counter market or any other quotation medium.
New Risk • Feb 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$65m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$65m free cash flow). Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (€8.54m market cap, or US$9.19m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$51m net loss in 3 years).
Board Change • Jan 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Independent Director Stacey Ma was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Independent Director Stacey Ma was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.